glp-1 employer healthcare costs spending in 2025: Why it's likely to accelerate Today in #Employer Coverage: GLP-1

The state obesity drug coverage landscape will continue to evolve as states respond to the recent announcement of the BALANCE model (see Box 1) and as states contend with budget challenges and the federal Medicaid spending cuts in the 2025 reconciliation law

Her thorough approach helps patients achieve sustainable results while managing any potential side effects or interactions with other treatments

136,169,170 With the accumulation of more clinical data and the development of new drugs, these treatment options are expected to provide more effective and comprehensive treatment choices for diabetes patients

This story originally appeared in the May 4, 2026 issue of Woman's World

Side effects may briefly reappear with dose increases but resolve faster each time